BridgeBio Pharma Inc (BBIO, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. BridgeBio Pharma Inc has a market cap of $4.03 billion; its shares were traded at around $32.59 with and P/S ratio of 142.52.
For the last quarter BridgeBio Pharma Inc reported a revenue of $13.8 million, compared with the revenue of $0.00 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $40.6 million, For the complete 30-year financial data, please go here..
The reported loss per diluted share was $2.48 for the year, compared with the loss per share of $0 in the previous year. The BridgeBio Pharma Inc had an operating margin of -656.41%, compared with the operating margin of 0% a year before. The profitability rank of the company is 1 (out of 10).
CEO Recent Trades:
- CEO and President Neil Kumar sold 30,893 shares of BBIO stock on 02/05/2020 at the average price of $34.87. The price of the stock has decreased by 6.54% since.
Directors and Officers Recent Trades:
- See Remarks Cameron Turtle sold 2,000 shares of BBIO stock on 02/11/2020 at the average price of $37.28. The price of the stock has decreased by 12.58% since.
- Chairman of Pharmaceuticals Charles J Homcy sold 20,000 shares of BBIO stock on 02/10/2020 at the average price of $36. The price of the stock has decreased by 9.47% since.
- See Remarks Neil Kumar sold 89,107 shares of BBIO stock on 02/04/2020 at the average price of $34.7. The price of the stock has decreased by 6.08% since.
- See Remarks Brian C Stephenson sold 10,800 shares of BBIO stock on 02/04/2020 at the average price of $34.73. The price of the stock has decreased by 6.16% since.
- See Remarks Michael Thomas Henderson sold 3,975 shares of BBIO stock on 02/03/2020 at the average price of $34.9. The price of the stock has decreased by 6.62% since.
For the complete 20-year historical financial data of BBIO, click here.
